Romero-Laorden, Nuria
Lozano, Rebeca
Jayaram, Anuradha
López-Campos, Fernando
Saez, Maria I.
Montesa, Alvaro
Gutierrez-Pecharoman, Ana
Villatoro, Rosa
Herrera, Bernardo
Correa, Raquel
Rosero, Adriana
Pacheco, María I.
Garcés, Teresa
Cendón, Ylenia
Nombela, Ma Paz
Van de Poll, Floortje
Grau, Gala
Rivera, Leticia
López, Pedro P.
Cruz, Juan-Jesús
Lorente, David
Attard, Gerhardt
Castro, Elena http://orcid.org/0000-0002-3691-6454
Olmos, David
Article History
Received: 25 November 2017
Revised: 17 April 2018
Accepted: 25 April 2018
First Online: 21 August 2018
Competing interests
: RL, GA, EC and DO have received research funding from Janssen. NRL, FLC, MIS, AM, BH, JJC, DL, GA, EC and DO have received speaker fees from Janssen. GA, EC and DO have received consulting fees from Janssen. AJ and GA are employees of The ICR, who developed abiraterone, and therefore have a commercial interest in this agent. GA is on the ICR list of rewards to inventors for abiraterone.
: The study was approved by the institutional ethics review committees of all participating centres and was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonisation/WHO Good Clinical Practice standards. All patients provided informed consent to enter the study at the time of enrolment.